HR and triple-negative breast carcinoma: Last, it was found that some triple-negative breast cancer (TNBC) cell lines showed sensitivity to palbociclib with obvious growth inhibition, and the efficacy of palbociclib on TNBC was irrespective of the status of HR and HER2 [49].